Back | Next |
home / stock / bmy / bmy message board
Subject | By | Source | When |
---|---|---|---|
$BMY 4Q22 CC transcript: | DewDiligence | investorshub | 02/02/2023 9:11:27 PM |
$BMYs Sotyktu patients are coming approximately 1/3 from | DewDiligence | investorshub | 02/02/2023 2:23:42 PM |
$BMY 4Q22 CC slides: | DewDiligence | investorshub | 02/02/2023 2:06:28 PM |
$BMY 4Q22 results2023 guidance: | DewDiligence | investorshub | 02/02/2023 1:26:59 PM |
CHMP approves $BMYs Sotyktu for psoriasis: | DewDiligence | investorshub | 01/27/2023 3:29:27 PM |
AddendumBreyanzi is the first CAR-T to show efficacy | DewDiligence | investorshub | 01/27/2023 12:54:38 AM |
$BMYs Breyanzi meets primary endpoint in rrCLL/SLL single-arm trial: | DewDiligence | investorshub | 01/26/2023 3:45:51 PM |
whytestocks: $BMY News Article - The Robert A. Winn Diversity in Clinical Trials Award Program Estab | whytestocks | investorshangout | 01/19/2023 5:50:46 PM |
$BMYs$ JPM webcast slides: | DewDiligence | investorshub | 01/09/2023 3:40:36 PM |
$BMYs Breyanzi continues to show robust results in | DewDiligence | investorshub | 12/12/2022 4:53:55 PM |
$BMYs ASH presentations: | DewDiligence | investorshub | 12/12/2022 2:54:46 PM |
$BMY boosts annualized dividend to $2.28(from $2.16): | DewDiligence | investorshub | 12/08/2022 10:38:14 PM |
whytestocks: $BMY News Article - Bristol Myers Squibb Data at ASH 2022 Highlight Innovative Therapeu | whytestocks | investorshangout | 11/21/2022 7:15:50 PM |
$BMYs ASH lineup: | DewDiligence | investorshub | 11/21/2022 2:44:19 PM |
$BMYs AHA presentation lineup: | DewDiligence | investorshub | 11/02/2022 1:04:58 PM |
$BMY scores phase-3 win for Reblozyl in a | DewDiligence | investorshub | 10/31/2022 3:45:41 PM |
$BMY 3Q22 CC transcript: | DewDiligence | investorshub | 10/26/2022 8:36:28 PM |
$BMY 3Q22 CC slides: | DewDiligence | investorshub | 10/26/2022 11:59:17 AM |
$BMY 3Q22 results2022 non-GAAP guidance unchanged: | DewDiligence | investorshub | 10/25/2022 11:48:51 PM |
Camzyos sNDA for prevention of SRT* in patients | DewDiligence | investorshub | 10/21/2022 12:48:52 PM |
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb Company Company Name:
BMY Stock Symbol:
NYSE Market:
Bristol-Myers Squibb Company Website:
NORTHAMPTON, MA / ACCESSWIRE / July 22, 2024 / Bristol Myers Squibb Company Our Approach to ESG At BMS, we understand that the future of our company, employees, communities, and the planet are inextricably linked. Our passion for making an impact extends beyond the discovery, development a...
The Application is based on Phase 3 CheckMate - 9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population Bristol Myers Squibb (NYSE: ...
SBTi validation affirms BMS' long-standing commitment to environmental stewardship PRINCETON, NJ / ACCESSWIRE / July 18, 2024 / Bristol Myers Squibb (NYSE:BMY) today announced validation for its near-term and net-zero science-based targets from the Science Based Targets initiative (SBTi), ...